Springvest’s sales don’t seem to be hindered by flying missiles, the orange man’s antics, or general uncertainty in the financial markets. An impressive feat to raise €8M for a drug development company in a few minutes. So much capital has already been raised for Desentum that it would be more relevant to consider its exit potential than the plausibility of the donut battery 
Ultimately, the company has proven to be quite defensive in recent years. Well-selected offerings are fully subscribed, operational results are being generated, and the growth company portfolio continues to grow and grow.